TGA extends approval for Vertex's cystic fibrosis therapy ahead of PBAC consideration

The TGA has approved Vertex's TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosisaged two to five who have at least one F508del mutation in the CF transmembrane conductance regulator gene. …